A Randomized, Double Blind, Active Comparator, Parallel-group Study to Determine Whether the Combination of Valsartan and Aliskiren Provides Cardioprotection in African American Patients With Hypertension and Elements of the Metabolic Syndrome

Trial Profile

A Randomized, Double Blind, Active Comparator, Parallel-group Study to Determine Whether the Combination of Valsartan and Aliskiren Provides Cardioprotection in African American Patients With Hypertension and Elements of the Metabolic Syndrome

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2013

At a glance

  • Drugs Aliskiren/valsartan (Primary) ; Ramipril
  • Indications Hypertension; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms SAAVE
  • Most Recent Events

    • 23 Aug 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 15 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top